[Orthokin as new therapeutic option for orthopedic diseases].
The synthesis and introduction of interleukin-1 receptor antagonists established a promising strategy in the treatment of inflammatory diseases. This kind of therapy is claimed now to be available for osteoarthritis and other orthopedic disorders also. In the case of "orthokin", the interleukin-1 receptor antagonist is produced by stimulation of own blood-cells. It is not possible, to evaluate the practicability of this therapeutic approach because there are no published experimental data. We also found no results of clinical studies, which would allow an estimation of the effectiveness and the risks of this method. Therefore treatment with "orthokin" cannot be recommended at present.
Heyll
U
U
Aus der Abteilung Medizinische Beratung der Deutschen Krankenversicherung, Köln.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D001804:Blood Transfusion, Autologous; D002074:Butanones / Q000008:administration & dosage* / Q000009:adverse effects; D005858:Germany; D006801:Humans; D007270:Injections, Intra-Articular; D000077430:Nabumetone; D010003:Osteoarthritis / Q000188:drug therapy* / Q000276:immunology; D011781:Quackery; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D017472:Receptors, Interleukin-1; D000077430:Nabumetone